These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 114736)

  • 21. Studies on guinea-pig macrophage migration inhibitory factor (MIF). II. Purification of MIF after treatment with reducing and denaturing agents.
    Kotkes P; Pick E
    Clin Exp Immunol; 1979 Sep; 37(3):540-50. PubMed ID: 389497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potentiation of the macrophage response to migration inhibition factor from fetal calf serum by blood group substances with human H activity.
    Fox RA; MacSween JM; McGuire RL
    Scand J Immunol; 1976; 5(8):941-7. PubMed ID: 792986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Affinity purification of macrophage migration inhibitory factor/glycosylation inhibiting factor (MIF/GIF) from bovine brain by using a peptide ligand derived from a novel serpin.
    Nishibori M; Nakaya N; Mori S; Kawabata M; Tahara A; Saeki K
    Jpn J Pharmacol; 1996 Jul; 71(3):259-62. PubMed ID: 8854209
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Possible role of macrophage glycolipids as receptors for migration inhibitory factor (MIF).
    Higgins TJ; Sabatino AP; Remold HG; David JR
    J Immunol; 1978 Sep; 121(3):880-6. PubMed ID: 357658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreased Fc and C3 receptor function in macrophage populations which are refractory to migration inhibitory factor, C3 activators, and immune complex.
    Leu RW; Hefley SM; Herriott MJ
    Cell Immunol; 1983 Aug; 80(1):31-42. PubMed ID: 6347401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of sialic acid in the macrophage glycolipid receptor for MIF.
    Liu DY; Petschek KD; Remold HG; David JR
    J Immunol; 1980 Apr; 124(4):2042-7. PubMed ID: 6988512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mouse spleen cell-derived toxoplasma growth inhibitory factor: its separation from macrophage migration inhibitory factor.
    Nagasawa H; Igarashi I; Matsumoto T; Sakurai H; Marbella C; Suzuki N
    Immunobiology; 1980 Dec; 157(4-5):307-19. PubMed ID: 7005083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generation of macrophage migration inhibitory activity by plasminogen activators.
    Roblin RO; Hammond ME; Bensky ND; Dvorak AM; Dvorak HF; Black PH
    Proc Natl Acad Sci U S A; 1977 Apr; 74(4):1570-4. PubMed ID: 193107
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Partial purification of the cholestatic factor derived from the lymphocytes of tuberculin-sensitized guinea pigs.
    Mizoguchi Y; Ohnishi F; Monna T; Yamamoto S; Morisawa S
    Gastroenterol Jpn; 1981; 16(3):260-7. PubMed ID: 7021301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interaction of Lotus-tetragonolobus Lectin (LTL) and an MIF-like factor with guinea-pig macrophages. I. Effects on macrophage migration inhibition and receptor-binding studies.
    Fahlbusch B; Wollweber L; Drössler K; Scherbaum I; Zschiesche W
    Immunobiology; 1982 Aug; 162(3):251-64. PubMed ID: 6752005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lotus tetragonolobus fucolectin as a potential model for "MIF-like" modulation of macrophage function: comparison of the interaction of Lotus fucose binding protein (FBP) and migration inhibitory factor (MIF) with macrophages in the migration inhibition assay.
    Leu RW; Whitley SB; Herriott J; Huddleston DJ
    Cell Immunol; 1980 Jul; 52(2):414-28. PubMed ID: 7002321
    [No Abstract]   [Full Text] [Related]  

  • 32. Inhibition of macrophage migration by virus-induced interferon preparations.
    Imanishi J
    Jpn J Microbiol; 1975 Oct; 19(5):337-42. PubMed ID: 1241396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The biochemical and biological characterization of macrophage migration inhibition factor isolated from fetal calf serum by affinity chromatography.
    Fox RA; MacSween JM; Rajaraman R
    Dev Comp Immunol; 1978 Feb; 2(1):147-60. PubMed ID: 346404
    [No Abstract]   [Full Text] [Related]  

  • 34. Partial characterization of murine migration inhibitory factor (MIF).
    Kühner AL; David JR
    J Immunol; 1976 Jan; 116(1):140-5. PubMed ID: 1107423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulatory mechanisms of cutaneous delayed-type hypersensitivity. I. Suppression of cutaneous delayed-type hypersensitivity by migration inhibitory factor.
    Mizushima A; Baba T; Ochiya T; Yamaguchi K; Onozaki K; Yaoita H; Uyeno K
    Cell Immunol; 1983 Oct; 81(1):126-33. PubMed ID: 6352055
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Partial purification and physicochemical properties of human T cell migration inhibitory factor (TIF).
    Kowalczyk D; Staykowa M; Litwora E; Pryjma J; Zembala M
    J Clin Lab Immunol; 1984 Oct; 15(2):105-10. PubMed ID: 6394762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Production of leucocyte inhibitory factor (LIF) and macrophage inhibitory factor (MIF) by PHA-stimulated lymphocytes.
    Ruthlomnitzer ; Rabson AR; Koornhof HJ
    Clin Exp Immunol; 1975 Dec; 22(3):522-7. PubMed ID: 773578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lymphokines. II. Use of horse monocytes as indicator cells for human MIF.
    Friedrich W; Lazary S; de Weck AL
    Int Arch Allergy Appl Immunol; 1976; 50(2):142-54. PubMed ID: 1107231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glycolipid affinity purification of migration inhibitory factor.
    Liu DY; David JR; Remold HG
    Nature; 1982 Mar; 296(5852):78-80. PubMed ID: 7038511
    [No Abstract]   [Full Text] [Related]  

  • 40. Production of an antibody against guinea pig MIF. III. Biological activity of MIF recovered from immunoadsorbent column chromatography.
    Onozaki K; Haga S; Ichikawa M; Homma Y; Miura K; Hashimoto T
    Cell Immunol; 1981 Jun; 61(1):165-75. PubMed ID: 7020954
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.